---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115033"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:53:46.690869+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zura Bio Q3 net loss $22.9M; cash $188.2M; Phase 2 trials on track for SSc and HS

## Summary
- Net loss of $22.9M ($0.26 per share) vs $8.3M ($0.18) in Q3 2023; G&A up $7.1M on one-time stock comp and warrant exchange.
- Cash, cash equivalents and investments $188.2M as of Sep 30, 2024, up from $99.8M at Dec 31, 2023; expected to fund operations through 2027.
- Phase 2 trial of tibulizumab for systemic sclerosis expected to initiate Q4 2024; Orphan Drug Designation request submitted to FDA.
- Phase 2 trial of tibulizumab for hidradenitis suppurativa anticipated to start Q2 2025; IND submission expected Q1 2025.
- Completed warrant exchange in August 2024 and established ATM program for financial flexibility.

## SEC filing metadata
- accession: 0001104659-24-115033
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465924115033/0001104659-24-115033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465924115033/tm2427543d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115033
- JSON: https://secwatch.observer/filing/0001104659-24-115033.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.